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Summary. Recent experimental work has challenged and shattered the old concept of a seques-
tration of pancreatic islet antigens from developing T-cells within the thymic environment. There
is now compelling evidence that the central immunological tolerance of the whole insulin family
may be induced during the process of T-cell ontogeny in the thymus. Transcripts of insulin-like
growth factor II (IGF-II), IGF-I and insulin genes have been characterized in human, rat and
mouse thymuses. At the peptide level, IGF-II was shown to be the dominant polypeptide of the
insulin family in the thymus from different species. Data are presented which support a dual
role of thymic IGF-II both in T-cell development as well as in T-cell negative selection. Using
animal models of autoimmune diabetes, current research is investigating the hypothesis that a
defect of thymic T-cell education to the insulin family is implicated in the pathophysiology of
human Type 1 diabetes. An efficient and secure prevention of Type 1 diabetes could be designed
on the basis of the strong natural tolerogenic properties of the thymus. Ó 1998 John Wiley &
Sons, Ltd.
1. INTRODUCTION
A fundamental property of the immune
system is its inability to react against the mol-
ecular structure of its host. In other words,
before reacting against “non-self” infectious
agents, the immune system must be tolerized
to the “self”. The induction of immune self-
tolerance is a multi-step process which begins
in the thymus during fetal development (central
tolerance) and which also involves inactivating
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or anergizing mechanisms outside the thymus
(peripheral tolerance).1 It is well established
today that the thymus is the primary lymphoid
organ involved in the development of com-
petent and self-tolerant T-cells.2 From a histo-
physiological point of view, three types of cells
have been described as constituents of the thy-
mic environment which control T-cell differen-
tiation. The predominant stromal cells (around
85%) are epithelial cells (TEC) which derive
from embryonic endoderm of the 3rd and 4th
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pharyngeal pouches. The contribution to the
thymic epithelium of the ectoderm from the
3rd branchial cleft is still a matter of discussion.
Among TEC of the outer cortex, thymic “nurse”
cells (TNC) provide a very specialized micro-
environment into which 50–150 immature T-
cells migrate and differentiate at contact of
these large epithelial cells.3,4 Bone marrow-
derived dendritic cells and macrophages rep-
resent the remaining components of thymic
parenchyme. They are dedicated professional
antigen-presenting cells although this property
is also shared by TEC/TNC.5 The dual physio-
logical role of the thymus in T-cell development
and in the negative selection of self-reactive T-
cells (by clonal deletion or developmental
arrest) remains a paradox hardly explained by
the available models. Indeed, it is problematic
to understand how two fundamental processes
such as T-cell life and death can be mediated
through a unique trimolecular complex: the
self-antigen, the major histocompatibility com-
plex (MHC)-encoded presenting protein and
the T-cell receptor for the antigen (TCR).6,7 On
the basis that TEC/TNC from different species
express a repertoire of neuroendocrine-related
polypeptides, we have proposed a model which
recapitulates at the molecular level the dual
physiological role of the thymus. Thymic
neuroendocrine-related precursors may engage
two distinct types of interactions with differen-
tiating T-cells.8,9 These precursors are a source
of cryptocrine signals which are targetted to the
outer surface of TEC/TNC plasma membrane
from where they can bind to neuroendocrine-
type receptors expressed by contacting thymo-
cytes (pre-T-cells). The same precursors can be
processed into neuroendocrine self-antigens which
are presented by the thymic MHC system.10,11
It is thought that the central T-cell tolerance of
neuroendocrine families could be mediated in
this way. Neuroendocrine self-antigens usually
correspond to peptide sequences which are
highly conserved throughout the evolution of
their family, and there is experimental evi-
dence, at least for some of them, that their
thymic presentation is not restricted in an
allelic fashion.12,13
2. HISTORICAL OVERVIEW OF
THYMIC INSULIN-LIKE POLYPEPTIDES
For a long time, an unbreakable frontier
was thought to separate pancreatic insulin-
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secreting islet b-cells and the developing T-
lymphocytes within the thymus. A series of
investigations have demonstrated that such a
concept is no longer valid and that the T-
cell system may be educated during thymic
ontogeny to recognize the molecular identity
of the pancreatic islet b-cell, i.e. the endocrine
secretion of insulin.
Already by 1965, on the basis that AKR
female mice develop hypoglycaemia and thy-
mic hyperplasia associated with lymphatic leu-
kaemia, Pansky et al. reported the presence of
an insulin-like peptide within the thymus from
AKR strain mice, as well as from bovine and
porcine species.14 Mouse thymic extracts
induced a marked hypoglycaemic effect when
subcutaneously injected into young (3–4 weeks
of age) female AKR mice. The biological action
of thymic extracts even exceeded that of simi-
larly prepared pancreatic extracts. Important
quantities of immunoreactive (IR) insulin (from
150 to .500 mU/g) could be extracted from the
thymus, in particular with acid–alcohol from
beef and pork thymus. Using fluorescein-
labelled guinea-pig anti-beef insulin, fluor-
escing elements were observed among reticular
cells and in Hassall’s corpuscles of pig thymus.
Interestingly, the authors discussed the agree-
ment of their data with previous studies
reporting hypoglycaemia associated with mass-
ive tumours of epithelial and mesodermal ori-
gin.15,16 They also postulated a role for this
thymic insulin-like reticular hormone in the
initiation of immunological competence and
lymphopoiesis.
To our knowledge, this thymic insulin-like
reticular biological and IR peptide has not been
further characterized. In 1987, however, Han et
al. described a wide distribution in human fetal
tissues of insulin-like growth factor (IGF) mess-
enger RNA (mRNA) by in situ hybridization
with oligonucleotides complementary to por-
tions of human IGF-I and IGF-II.17 In the fetal
thymus, IGF transcripts were found in the cap-
sule and in interlobular septa with a relative
predominance of IGF-II transcripts. No IGF
mRNAs could be evidenced in thymocytes. It
has to be noted, however, that other authors
failed to detect IGF-I mRNA in human fetal
tissues.18 Through the use of immunocytochem-
istry, IGF-IR-positive cells were found in the
corpuscles and interlobular septa of human
fetal thymus.19 The positive cells were
described as having the morphology of imma-
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ture haematopoietic precursors. Since the anti-
bodies recognized both IGF-I and IGF-II, the
identification of specific IGFs was precluded.
The relative quantification of IGF transcripts in
the human fetal thymus revealed two-fold more
IGF-II (625 pg/10 mg poly A+ RNA) than IGF-
I mRNAs (612 pg/10 mg poly A+ RNA),20 sug-
gesting that IGF-II is synthesized in greater
quantities than IGF-I in this organ during
embryonic development.
Since central T-cell tolerance of neuroen-
docrine functions could be induced by the thy-
mic repertoire of neuroendocrine self-anti-
gens,21 a series of investigations was initiated
in order to identify the dominant member of
the insulin family expressed in the thymic
microenvironment. Using a panel of specific
antibodies directed against several members
and epitopes of the insulin family, IR IGF-
II was clearly identified within TEC of the
subcapsular cortex and the medulla of human
and rat thymus.22 A monoclonal antibody
(mAb) against human proinsulin23 revealed a
slight labelling outside thymic lobules, in the
interstitial tissue of interlobular septa and the
thymic capsule. The staining with mAbs to the
C-terminal part of the bovine insulin B chain
(OXI-002 and OXI-005, Novo Nordisk) was
mainly negative within the thymic stroma,
while a slight labelling could be observed in
connective components. Some IGF-I-positive
cells were also identified in thymic lobules but
these cells were not epithelial; their distribution
and morphology were similar to macrophages.
Further characterization of thymic IR IGF-II
confirmed that 665% of the immunoreactivity
corresponds to recombinant human IGF-II. IR
IGF-II was not detected in the supernatant of
primary cultures of human TEC, either in basal
conditions or after treatment with epidermal
growth factor. However, a large part part of
IR IGF-II was shown to be associated with TEC
membranes. Using specific radioimmunoassays,
IGF-II was also shown to be the dominant
thymic peptide of the insulin family. In the
human thymus, IGF-II, IGF-I and insulin con-
centrations were respectively 96.7 6 10.6 ng/g,
42.9 6 5.0 ng/g and ,0.1 ng/g wet weight.
Using confocal microscopy and immunocytoch-
emistry with specific antibodies, IGF-II (but
neither IGF-I nor insulin) was detected at the
outer surface of TEC plasma membrane
(Achour et al., submitted). IGF-II transcripts
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have been isolated from whole human thymic
extracts, as well as from primary cultures of
human TEC. Through the use of polymerase
chain reaction (PCR) with different primers, the
intrathymic expression of the IGF-II gene was
found to be under the control of the same
promoters as in other fetal and adult extrahep-
atic tissues.24,25
The effects of IGF-II overexpression were
investigated by the generation of transgenic
mice carrying one of three different human
IGF-II minigenes in which different non-coding
exons (exon 5, truncated exon 5 or exon 6)
preceded the coding exons 7, 8 and 9. The
three IGF-II minigenes were placed under the
control of the MHC H-2Kb promoter. The high-
est levels of IGF-II minigene mRNA expression
were detected in lines containing the truncated
exon 5 construct. The highest mRNA expression
was found in thymus and spleen; serum IGF-
II levels at 8 weeks of age were increased
seven- to eight-fold in homozygous transgenic
lines but no significant hypoglycaemia was
observed. Among several organs, only the thy-
mus showed a significant increase of weight in
these transgenics, in agreement with the high
mRNA expression within this organ.26 With
in situ hybridization, expression of the IGF-II
transgene was found with high intensity in the
thymic medulla and in the white
pulp/marginal zone of the spleen, whereas
there were scattered positive cells in the thymic
cortex and in the splenic red pulp. Hybridiz-
ation was restricted to non-lymphocytic cells
and immunocytochemistry revealed intense
IGF-II peptide staining with the same distri-
bution of IGF-II mRNA.27
Going back to the initial observations made
by Pansky et al,14 there is now ample evidence
that the thymic insulin-like reticular factor cor-
responds in fact to IGF-II. The IGF-II structure
closely related to (pro)insulin might explain a
cross-reactivity with the antibodies against
insulin used at that time. The hypoglycaemic
properties of IGF-II have been well described28
and might also explain the biological activity
of thymic extracts on glucose metabolism. The
syndrome of hypoglycaemia and lymphatic leu-
kaemia associated with thymic hyperplasia of
some AKR female mice could result from an
overexpression of Igf2 in hyperplasic thymic
epithelium, a subsequent secretion of IGF-II
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in the bloodstream, as well as a profoundly
disturbed intrathymic lymphopoiesis.
The hypothesis for a central T-cell tolerance
of the peripheral pancreatic islets was further
supported by the observation that transcripts
of insulin, glucagon, somatostatin, pancreatic
polypeptide and the 67 kDa isoform of glutamic
acid decarboxylase could be detected in the
murine thymus using PCR with 30 cycles of
amplification.29 Thymic insulin gene (INS)
expression was strongest in perinatal mice and
persisted until 12 weeks of age. Two recent
papers confirmed these findings and reported
that INS transcripts, as well as (pro)insulin pro-
tein, are detected at low levels in the human
fetal thymus. Thymic concentrations of insulin
IR were 98–1200 fmol/g wet weight in the first
study,30 whereas proinsulin concentrations were
1.904 6 1.428 SD pmol/mg protein and those
of insulin were 0.437 6 0.218 SD pmol/mg pro-
tein in the second study.31 Since long class III
variable number tandem repeat (VNTR) alleles
(140–210 repeats) are associated with two- to
three-fold higher thymic INS mRNA levels, the
authors suggested that the protective effect of
these alleles against Type 1 diabetes could be
explained by the higher level of thymic INS
expression, thereby facilitating the induction of
central immunological self-tolerance of insulin.
Using in situ hybridization, INS transcripts have
been detected in thymic dendritic cells although
the protein could not be detected by immuno-
cytochemistry (F. Homo-Delarche, personal
communication). The induction of a strong
tolerogenic action by thymic (pro)insulin may
nevertheless be questioned. Thymic (pro)insulin
concentrations are very low and thymic T-cell
tolerance rapidly decreases for peptide concen-
trations below 10 nM.32,33 In addition, a recent
discussion was raised about the precise bound-
aries of the IDDM2 locus of susceptibility to
Type 1 diabetes which could also include two
genes close to the INS VNTR, the tyrosine
hydroxylase and IGF2.34,35 There is also strong
evidence that implicates an imprinted gene in
the INS-IGF2 region of chromosome 11p15 in
the aetiology of Type 1 diabetes. Since INS is
not imprinted in the human fetal pancreas, the
monoallelic expression of IGF2 in the thymus
might explain why insulin-dependent diabetes
is transmitted by diabetic fathers more than
twice as often as by diabetic mothers.36
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3. THE DUAL PHYSIOLOGICAL ROLE
OF THYMIC IGF-II
A functional signalling mediated by IGF-II
and IGF receptors is plausible between
TEC/TNC and immature T-cells since type 1
and type 2 IGF receptors are detected in rat
thymocytes and murine thymoma cells,37 on
human phytohaemagglutinin (PHA)-activated
T-cells and on anti-CD3-activated human T-
lymphocytes.38,39 Kooijman et al. have described
a differential expression of type 1 IGF receptors
in relation to the stage of activation and differ-
entiation of human T-lymphocytes.40 Interest-
ingly, in IGF-II transgenic mice the increased
thymic cellularity is associated with a stimu-
lated generation of phenotypically normal T-
cells, in particular CD4+ T-cells.41 In our hands,
specific type 2 IGF receptors were found to be
expressed by a murine immature T-cell line as
well as by Jurkat T-cells.42 By affinity cross-
linking, the type 2 IGF receptor expressed by
lymphocytes was shown to have a molecular
mass (6260 kDa) similar to that found on other
cells (Goxe et al., in preparation). On the basis
of these observations, thymic IGF-II may thus
intervene in a functional cryptocrine signalling
between TEC and pre-T-lymphocytes during
their intrathymic developmental programme.
As discussed earlier, IGF-II was found to
be the dominant member of the insulin hor-
mone family expressed by TEC/TNC from dif-
ferent species. Thymic IGF-II concentrations are
high (6100 ng/g) and it has been shown that
the final orientation of an antigen-driven
immune response, towards either priming
(immunogenic) or tolerizing (tolerogenic), is
determined by the dominant T-cell epitopes.43
Thus, if a tolerogenic immune response follows
the thymic expression of an insulin-related pro-
tein, this should firstly concern the dominant
thymic peptide of the insulin family. Thymic
IGF-II may induce a strong central immune
tolerance of IGFs similar to that observed for
peripheral proteins resulting from their thymic
expression.44 The crucial role of IGFs in fetal
and postnatal development implies that these
proteins have to be protected from an auto-
immune attack. As an important though
indirect argument for the tolerogenic properties
of IGF-II, it is known that the production of
specific antibodies is much more difficult with
IGF-II than with insulin or IGF-I.45,46 The IGF-
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II molecule includes peptide sequences which
are highly conserved throughout the evolution
of the insulin family.47 Because of this close
homology, thymic IGF-II would be a good can-
didate for inducing central immune tolerance
of the insulin family although the tolerance of
insulin per se would be weaker. This might
explain why B- and T-cell autoreactivity to
insulin has been equally observed in diabetic
and related non-diabetic individuals.48
4. RELATIONSHIPS BETWEEN THE
THYMUS AND TYPE 1 DIABETES
The question of a defective thymic censor-
ship as one element implicated in the patho-
physiology of autoimmune diabetes has not
been intensively investigated until now. Some
elegant studies, however, have provided experi-
mental arguments supporting this idea. Neo-
natal thymectomy prevents the emergence of
diabetes in an animal model of Type 1 diabetes,
the Bio-Breeding (BB) rat.49 The benefit of thy-
mectomy might in fact result from the removal
of a defective organ responsible for the contin-
ual release and the peripheral enrichment of
intolerant self-reactive T-lymphocytes. Con-
versely, the occurrence of diabetes is prevented
by the transplantation of thymus from diabetes-
resistant to diabetes-prone BB rats.50 Trans-
plantation of the thymus from NOD mice to
Table I. The dual role of thymic IGF-II in T-cell
differentiation
IGF-II or IGF-II-derived
Cryptocrine signalling self-antigen presentation
Physiology Physiology
Accessory pathway Central T-cell tolerance of
in T-cell development the insulin family and
islet b-cells
Pathophysiology Pathophysiology




Immunomodulation by Tolerogenic vaccination
IGF agonists and
antagonists
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diabetes-resistant mouse strains was also shown
to induce diabetes in the recipients.51 While
bone marrow transplantation is ineffective in
autoimmune diseases of MRL/+ mice, thymus
transplantation was found to be a crucial factor
for their prevention.52 An abnormal process of
thymic T-cell selection has been suggested on
the basis that diabetes-resistant BB rat thymus
contains thymocytes predisposed to autoreac-
tivity.53 As another argument for a role of thy-
mic T-cell repertoire selection in the pathogen-
esis of autoimmune diabetes, grafts of pure
thymic epithelium from NOD mouse embryos
to newborn C57BL/6 athymic mice were shown
to induce CD4 and CD8 T-cell-mediated insul-
itis and sialitis.54 At the histological level, a
defect in thymic censorship could result from a
disorganization in the tissue microenvironment
such as the giant perivascular spaces observed
in the NOD mouse thymus55 and the epithelial
defects of BB rat thymus.56 Altogether these
observations support the hypothesis that a
defective thymic induction of central T-cell tol-
erance plays a role in the pathophysiology of
Type 1 diabetes. IGF IR elution profiles on G75
columns were analysed in thymic extracts from
Wistar Furth (WF), diabetes-resistant and dia-
betes-prone BB rats. A peak of .10 ng/ml was
observed in the elution profile of WF thymus
extract; a peak around 1.5 ng/ml was eluted
from diabetes-resistant BB rat thymus extract,
while IGF-II concentrations were almost unde-
tectable in the thymus from diabetes-prone BB
rats.57 These observations strongly suggest at
the molecular level that a defect in thymic IGF-
II-mediated T-cell education might be
implicated in the pathogenesis of autoimmune
insulin-dependent diabetes.
5. TOWARDS A TOLEROGENIC FORM
OF VACCINATION FOR THE
PREVENTION OF TYPE 1 DIABETES?
Three factors are thought to be implicated
in the pathophysiology of Type 1 diabetes. (1)
The effector components are CD4 and CD8
autoreactive T-cells which are specifically ori-
ented against the pancreatic islet insulin-
secreting b-cells. These autoreactive T-cells
could result from a spontaneous breakdown of
T-cell tolerance, either at the central and/or the
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peripheral level. (2) A series of extra- and intra-
MHC genes have been demonstrated to be
related to Type 1 diabetes. Some of these genes
probably intervene in the presentation of islet
autoantigens to autoreactive T-lymphocytes,
but others certainly not. (3) An environmental
factor is finally involved and could establish a
pathogenetic link between pancreatic islet auto-
antigens and autoreactive T-cells. The hypoth-
esis of a molecular mimicry between islet auto-
antigens and microorganisms might intervene
at this level and has recently received an inter-
esting experimental support.58 The intervention
of microbial superantigens has also been pro-
posed to account for the activation of peripheral
autoreactive T-cells.59 A preventive strategy of
Type 1 diabetes can hardly be designed on the
basis of the genetic components of the disease
or the hazardous external factors. Manipulation
of autoreactive T-cells seems to be a more
promising way by which an efficient prevention
could be designed.
There is now considerable evidence that
insulin is one among other autoantigens tackled
by various autoreactive components of the
immune system in both animal and human
Type 1 diabetes.60,61 Moreover, insulin is a spe-
cific marker of the islet b-cells. Oral, intranasal
and parenteral administration of insulin or
insulin-derived dominant autoantigens have
been shown to inhibit the occurrence of dia-
betes in animal models of Type 1 diabetes.62,63
However, one cannot exclude the risk of trig-
gering autoimmunity by peripheral adminis-
tration of an autoantigen.64 Reprogramming the
immune tolerance which is thought to be
broken in autoimmunity represents an attract-
ive srategy for the prevention of devastating
autoimmune diseases such as Type 1 diabetes.
Such reprogramming could be based on the
natural tolerogenic properties of the thymic epi-
thelium. Instead of a classical “vaccination”
(with immune activation and induction of
“memory” immunocompetent cells), a form of
“tolerogenic” vaccination is proposed that
would lead to the deletion or the anergy of
peripheral autoreactive T-cells. The induction
of T-cell tolerance following peptide vaccination
has already been obtained with synthetic pep-
tides representing cytotoxic CD8 epitopes of T-
cells oriented against tumours or viruses.65 An
efficient and non-toxic prevention of Type 1
diabetes, perhaps even its definitive eradication,
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could depend upon the strategic choice that
will be made between either the induction of
tolerance to b-cell-specific autoantigens (such as
insulin, glutamic acid decarboxylase, or others)
following their parenteral administration, or the
exploitation of the natural tolerogenic proper-
ties of thymic IGF-II, the self-antigen precursor
of the insulin hormone family.
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